Aging Relevant Metabolite Itaconate Inhibits Inflammatory Bone Loss

Area of Science:

• Gerontology
• Immunology
• Bone Biology

Background:

• Osteoporosis is a prevalent condition in aging populations, characterized by progressive bone loss.
• Bone homeostasis relies on osteoblast and osteoclast activity, which can be disrupted by inflammaging.
• The impact of aging-related inflammation and metabolites on osteoclast regulation is not well understood.

Purpose of the Study:

• To investigate the role of the anti-inflammatory metabolite itaconate in regulating osteoclast function during aging.
• To determine if itaconate can mitigate inflammatory bone loss associated with aging.

Main Methods:

• Observation of itaconate levels and reactivity in aged macrophages.
• Assessment of itaconate's effect on osteoclast differentiation and activation in vitro.
• Evaluation of itaconate's efficacy in an animal model of inflammatory bone loss.

Main Results:

• Itaconate levels are elevated in aged macrophages, but their response to RANKL stimulation is reduced.
• Itaconate demonstrates an inhibitory effect on osteoclast differentiation and activation.
• Itaconate successfully rescued bone loss in a lipopolysaccharide-induced inflammatory bone loss animal model.

Conclusions:

• Itaconate plays a critical role in regulating osteoclast activity during inflammaging.
• Itaconate acts as a protective metabolite, inhibiting osteoclast function to maintain bone homeostasis in aging.
• Targeting itaconate pathways may offer a therapeutic strategy for age-related bone loss.